Table 3.

Population parameter estimates of the final PD models (sVEGFR‐2 and sVEGFR‐3)

Parameter	Unit	Estimate (RSE, %)	IIV (RSE, %)	Bootstrap mean	Bootstrap 90% CI
sVEGFR‐2
Baseline	µg/L	9.0 (2.9)	19.9 (21.4)	9.0	8.6–9.5
α	‐	2.31 (8.8)	‐	2.31	1.98–2.64
kout	1/h	0.0043 (7.6)	‐	0.0043	0.0038 to −0.0049
Kd	µg/mL	4a	‐	4a	‐
Residual error	‐	0.124 (6.8)	‐	0.122	0.108–0.136
Tumor type on α (proportional)	‐	−0.328 (24.6)	‐	−0.322	−0.440 to −0.186
VEGFR‐3 rs6877011 on α (proportional)	‐	−0.565 (25.4)	‐	−0.557	−0.787 to −0.319
ABCB1 rs2032582 on α (proportional)	‐	−0.311 (37.9)	‐	−0.307	−0.497 to −0.117
sVEGFR‐3
Baseline value	µg/L	63.5 (5.9)	42.6 (24.4)	63.7	57.3–69.8
α	‐	1.74 (9.8)	54.3 (43.5)	1.76	1.49–2.05
kout	1/h	0.0053 (7.2)	‐	0.0054	0.0047 to −0.0060
Kd	µg/mL	4a	‐	4a	‐
Residual error	‐	0.15 (6.9)	‐	0.15	0.13–0.17
Tumor type on baseline value (proportional)	‐	−0.642 (6.5)	‐	−0.640	−0.703 to −0.569
Correlations
ρ (baseline value, α)	‐	0.124	‐	0.123	0.045–0.209

α, intrinsic activity; CI, confidence interval; IIV, interindividual variability; k_d, dissociation constant; k_out, elimination rate constant; ρ, correlation coefficient; PD, pharmacodynamic; RSE, relative standard error; sVEGFR, soluble vascular endothelial growth factor receptor; VEGFR, vascular endothelial growth factor receptor.

^aParameter fixed to literature value.